Biotech M&A: What Big Pharma Buyers Look For
Big drug makers buy biotech companies to replace revenue they are about to lose when their best-selling drugs lose patent protection. They mostly pay for drugs with good clinical data in large markets. Takeover premiums of 30% to 50% or more over the share price are common in large deals, but betting on a takeover rumor is risky, because most rumored deals never happen.
Why big pharma buys biotechs
A large drug maker's biggest products all lose patent protection eventually, and when they do, cheap copies take most of the sales within a few years. Building a replacement in-house takes a decade and usually fails. Buying a company whose drug already works is faster and, at the right price, less risky.
That pressure, often called the patent cliff, is why big deals cluster when several blockbusters are nearing the end of their protection at once.
What makes a biotech a takeover target
- Clinical proof. Strong Phase 2 or Phase 3 data lowers the buyer's risk.
- A big market. Buyers need drugs that can sell billions, not millions.
- A fit. The drug matches what the buyer already sells or wants to sell.
- Clean ownership. No partner holding the key rights.
- A price that works. A beaten-down stock with good data is easier to buy than one already priced for success.
Three real deals and their premiums
| Deal | Price / premium |
| Pfizer buys Seagen (March 2023) | $43 billion, about 33% over the prior close |
| Bristol Myers Squibb buys Karuna (December 2023) | $14 billion, about 53% premium |
| Johnson & Johnson buys Intra-Cellular (January 2025) | $14.6 billion, about 39% premium |
Seagen sold approved cancer drugs. Karuna had a schizophrenia drug under FDA review. Intra-Cellular had an approved drug with a new use coming. Each one was a de-risked, large-market product that filled a gap for the buyer.
The risk of buying for a takeover
Takeover talk is everywhere in biotech, and most of it never turns into a deal. A stock that rises on a rumor can give it all back when nothing happens. Many experienced biotech investors look instead at whether a company would hold up without a deal, with good data, enough cash and specialist funds holding, and see a takeover as a possible extra rather than the plan.
See it live: Biotech deals as they are announced, plus acquisition-likelihood scores for possible targets.
Open the M&A Tracker →Frequently asked questions
Mainly to replace sales they will lose when their top drugs lose patent protection. Buying a company with a working drug is faster and often less risky than developing one in-house.
It varies widely, but premiums of 30% to more than 50% over the share price are common in large deals. Pfizer paid about 33% for Seagen, Bristol Myers Squibb about 53% for Karuna and J&J about 39% for Intra-Cellular.
Look for companies with strong clinical data in large markets, clean rights to their drugs and a valuation a buyer can justify. Our M&A tracker scores companies on how closely they match past targets.
Rumors are a risky reason on their own. Most rumored deals never happen, and the stock can fall back when they don't. That is why many investors judge a company on what it is worth without a deal.
The point when a drug's patent protection ends and cheaper copies can enter, usually cutting its sales sharply within a few years.
Educational content only. Not financial advice. Past results don't predict future ones.